iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer
NCT03867799 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25
Last updated 2024-06-14
Summary
This is a single-arm, single centre open-label, phase II interventional clinical trial of combination immunotherapy with Nivolumab and Relatlimab in mCRC.
Conditions
Interventions
- DRUG
-
Immunotherapy
Sponsors & Collaborators
-
Royal Marsden NHS Foundation Trust
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-03-27
- Primary Completion
- 2022-10-21
- Completion
- 2024-09-30
Countries
- United Kingdom
Study Locations
More Related Trials
-
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
NCT04008030 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
NCT00856375 ·Status: COMPLETED ·Phase: PHASE2
-
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
NCT03233711 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
The Safety and Efficacy Test of Immuncell-LC to Treat Refractory Metastatic Colorectal Cancer
NCT03220984 ·Status: UNKNOWN ·Phase: PHASE2
-
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread
NCT03377361 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer
NCT02314169 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC
NCT06643793 ·Status: RECRUITING ·Phase: PHASE2
-
Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer
NCT04751370 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer
NCT03981146 ·Status: COMPLETED ·Phase: PHASE2
-
Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
NCT04912765 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)
NCT04907539 ·Status: COMPLETED ·Phase: PHASE2
-
Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer
NCT06522919 ·Status: RECRUITING ·Phase: PHASE2
-
Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer
NCT06341296 ·Status: RECRUITING ·Phase: PHASE2
-
Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy
NCT06414304 ·Status: COMPLETED
-
Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer
NCT03026140 ·Status: RECRUITING ·Phase: PHASE2
-
Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer
NCT00032110 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer
NCT03567629 ·Status: UNKNOWN ·Phase: PHASE2
-
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
NCT03169777 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer
NCT06184698 ·Status: RECRUITING ·Phase: PHASE2
-
Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer
NCT03186326 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer
NCT00569335 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
NCT06959550 ·Status: RECRUITING ·Phase: PHASE2
-
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer
NCT01675128 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors
NCT02488759 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients
NCT03053167 ·Status: UNKNOWN ·Phase: PHASE2